Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures.
Aneuploidy, an abnormal number of chromosomes, has previously been considered irremediable. Here, we report findings that euploid cells increased among cultured aneuploid cells after exposure to the protein ZSCAN4, encoded by a mammalian-specific gene that is ordinarily expressed in preimplantation embryos and occasionally in stem cells. For footprint-free delivery of ZSCAN4 to cells, we developed ZSCAN4 synthetic mRNAs and Sendai virus vectors that encode human ZSCAN4. Applying the ZSCAN4 biologics to established cultures of mouse embryonic stem cells, most of which had become aneuploid and polyploid, dramatically increased the number of euploid cells within a few days. We then tested the biologics on non-immortalized primary human fibroblast cells derived from four individuals with Down syndrome—the most frequent autosomal trisomy of chromosome 21. Within weeks after ZSCAN4 application to the cells in culture, fluorescent in situ hybridization with a chromosome 21-specific probe detected the emergence of up to 24% of cells with only two rather than three copies. High-resolution G-banded chromosomes further showed up to 40% of cells with a normal karyotype. These findings were confirmed by whole-exome sequencing. Similar results were obtained for cells with the trisomy 18 of Edwards syndrome. Thus a direct, efficient correction of aneuploidy in human fibroblast cells seems possible in vitro using human ZSCAN4.
Elixirgen, LLC, Science + Technology Park at Johns Hopkins, 855 N Wolfe Street, Suite 621, Baltimore MD 21205-1511, USA.
Tomokazu
T
Amano
Elixirgen, LLC, Science + Technology Park at Johns Hopkins, 855 N Wolfe Street, Suite 621, Baltimore MD 21205-1511, USA.
Emiko
E
Jeffries
Elixirgen, LLC, Science + Technology Park at Johns Hopkins, 855 N Wolfe Street, Suite 621, Baltimore MD 21205-1511, USA.
Misa
M
Amano
Elixirgen, LLC, Science + Technology Park at Johns Hopkins, 855 N Wolfe Street, Suite 621, Baltimore MD 21205-1511, USA.
Akihiro C
AC
Ko
Elixirgen, LLC, Science + Technology Park at Johns Hopkins, 855 N Wolfe Street, Suite 621, Baltimore MD 21205-1511, USA.
Hong
H
Yu
Elixirgen, LLC, Science + Technology Park at Johns Hopkins, 855 N Wolfe Street, Suite 621, Baltimore MD 21205-1511, USA Department of Systems Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160, Japan ko.minoru@elixirgen.com.
Minoru S H
MS
Ko
D000782:Aneuploidy; D000818:Animals; D002478:Cells, Cultured; D002887:Chromosomes, Human, Pair 18 / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D004314:Down Syndrome / Q000517:prevention & control*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D051379:Mice; D000066450:Mouse Embryonic Stem Cells; D061251:Primary Cell Culture; D012333:RNA, Messenger / Q000235:genetics; D029082:Sendai virus; D014157:Transcription Factors / Q000235:genetics*; D014314:Trisomy / Q000235:genetics*; D000073842:Trisomy 18 Syndrome
D004268:DNA-Binding Proteins; D012333:RNA, Messenger; D014157:Transcription Factors; C582979:ZSCAN4 protein, human
Down syndrome; Edwards syndrome; ZSCAN4; aneuploidy; human fibroblast cells